DCOY logo

Decoy Therapeutics Inc. Stock Price

NasdaqCM:DCOY Community·US$5.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

DCOY Share Price Performance

US$0.82
-54.23 (-98.51%)
US$0.82
-54.23 (-98.51%)
Price US$0.82

DCOY Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with moderate risk.

5 Risks
0 Rewards

Decoy Therapeutics Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$5.0m

Other Expenses

-US$5.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.78
0%
0%
0%
View Full Analysis

About DCOY

Founded
n/a
Employees
2
CEO
Frederick Pierce
WebsiteView website
decoytx.com

Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Cambridge, Massachusetts.

Recent DCOY News & Updates

Recent updates

No updates